NIH's 2026 High-Risk, High-Reward Class: 58 Awards, $237.5 Million, 42 New Innovators — and Early Independence Cut to Three

On October 6, 2026, NIH announced its new High-Risk, High-Reward Research cohort: 58 grants totaling about $237.5 million, starting in 2026 and running up to five years, subject to available funds. Taken alone, that's a routine announcement. Next to the three previous cohorts, it shows NIH changing what the program funds and how much it pays per award.

The breakdown:

2024–2026 program counts and totals are from NIH Common Fund announcements. The 2023 total and award count are as reported by NIH. Averages are announced totals divided by award count and reflect multi-year commitments, not annual budgets.

These numbers point to three trends, and each affects how you should approach the next two cycles.

Trend 1: fewer awards, more money per award

The number of awards fell from 85 in 2023 to 58 in 2026, a drop of about a third. Total dollars rose about 27 percent over the same period. Average announced value per award nearly doubled, from about $2.2 million to about $4.1 million.

Some of the rise comes from the mix of awards. Early Independence awards are the cheapest of the four, and replacing ten of them with New Innovator awards raises the average. But mix alone doesn't account for it. Pioneer awards, the most expensive mechanism with up to $700,000 a year in direct costs under the 2025 concept clearance, actually fell from 8 to 7. New Innovator, at $300,000 a year in direct costs under that clearance, accounts for nearly three-quarters of the 2026 class.

The likeliest explanation is the one we found in the FY2028 forecast: the program's dollar figures assume full negotiated indirect rates and full five-year commitments. The FY2027 New Innovator RFA had already raised the direct-cost ceiling to $475,000 a year (see our DP2 analysis). A five-year commitment at that size, with indirect costs added, easily exceeds $3 million.

What this means for applicants: HRHR is now paying for fewer, larger bets. The budget is no longer a reason to scale back an ambitious New Innovator idea. Reviewers are judging whether the idea justifies a multi-million-dollar, five-year commitment to a single investigator, and the application should be written to that standard.

Trend 2: New Innovator recovered, and co-funders made it possible

New Innovator dropped to 29 awards in 2025, its lowest count in recent years, and came back to 42 in 2026, above the 2024 level.

Look at who paid for it. The 2026 cohort lists four funders: the NIH Common Fund, the National Institute of Environmental Health Sciences (NIEHS), the National Institute on Deafness and Other Communication Disorders (NIDCD), and the Office of Research Innovation, Validation, and Application (ORIVA). In 2025 the co-funders were NIMH and the Office of Dietary Supplements. In 2024 they were NIGMS, NIMH, and the National Library of Medicine.

The Common Fund's own HRHR budget is modest. The FY2027 slate we analyzed in August planned for about 30 New Innovator awards. Counts above the Common Fund's base usually come from institutes and offices that choose to pay for applications that scored well in their own mission areas.

Two strategic points follow:

1. Co-funders change from year to year, and they matter at the margin. An application that scores just below the Common Fund payline but squarely within an institute's mission can be funded through that institute. NIEHS and NIDCD funded part of this cohort, so environmental health and hearing, balance, voice, speech, and language research had a slightly better chance in 2026. That won't necessarily hold next year.
2. ORIVA's participation is new and should be watched. ORIVA is NIH's office focused on validating and applying research. Its presence among co-funders suggests that work with a plausible validation or application path got extra consideration this year. The program still doesn't require translational potential, but a New Innovator idea that pairs scientific novelty with a believable route to use now has another possible funder.

The themes NIH highlighted in its announcement match this reading: AI-accelerated cancer treatment discovery, restoring natural speech for stroke survivors (a clear NIDCD fit), placental biology for preeclampsia, and repurposing existing drugs for hundreds of rare diseases.

Trend 3: Early Independence was the casualty

Early Independence went from 13 awards in 2025 to 3 in 2026, a 77 percent drop.

This isn't a sudden policy change, and it's explainable. As we reported in August, the FY2026 Early Independence funding opportunity never went forward. The program skipped a year. The FY2027 competition (RFA-RM-27-004, due September 10, 2026) used an unusually wide degree-eligibility window of about 29 months to cover the gap. NIH's release doesn't say how three Early Independence awards were made in 2026 without a FY2026 competition. Whatever the source, the 2026 count reflects a gap year, not the program's normal size.

The FY2027 slate projects about 10 Early Independence awards, and the FY2028 forecast holds that at 10 with $350,000 per award. So the mechanism is coming back, but at a smaller size than the 12–13 awards of 2024–2025.

For graduate students and medical residents considering the skip-the-postdoc route: expect about 10 national awards a year, each requiring institutional nomination. That means your institution's internal competition is the real bottleneck. The FY2028 RFAs are expected to post around March 15, 2027. Find out your institution's nomination timeline now, because it will run months ahead of NIH's deadline.

What the timing tells you

The 2026 cohort was announced on October 6, about six weeks earlier than 2025's November 20 date and close to 2024's October 8. Together with the record 1,648 early-stage investigator R01 equivalents announced three days later, it suggests NIH obligated its early-career commitments on schedule in FY2026, despite agency-wide concerns about unobligated balances.

That's encouraging for current FY2027 applicants. The Transformative (September 3), Pioneer (September 9), and Early Independence (September 10) applications submitted last month, and the New Innovator applications submitted August 17, are in a program that is paying out on time.

One terminology change to note

NIH's announcement page includes a note that federal agencies now use "Super Intelligence (SI)" in place of "Artificial Intelligence (AI)" under Executive Order 14434. NSF has said the same about its own grant documents. This doesn't change how anything is scored. But program officers, RFA text, and reviewer guidance will increasingly use the new term, and applicants writing about computational methods should know both labels may appear in the same solicitation. Use whichever one the RFA uses.

Strategy for the next two cycles

If you applied in the FY2027 cycle: Award decisions for the September 2026 applications are expected next summer and fall. Don't wait for that result before planning a FY2028 application. The FY2028 RFAs will post around March 15, 2027, before you hear back on FY2027. Build the FY2028 version in parallel and treat the two as separate shots.

If you're a New Innovator candidate: The 2026 class shows the mechanism is healthy and well funded. Check your Early Stage Investigator window against the FY2028 New Innovator due date, which is forecast for August 19, 2027. If your ESI status lapses before then, FY2028 isn't your year, and it's better to know that now.

If you're targeting Pioneer: It's the most selective of the four (7 awards in 2026, and the forecast holds it near 7). Pioneer rewards a new research direction, not a continuation of what you already do. Use the next five months to develop the "new direction" framing, which is the part of the essay reviewers judge most harshly.

If you're assembling a Transformative team: The mechanism has held at 6–7 awards for three years. As we noted in the forecast analysis, the collaboration has to be real before you apply: shared data, a joint pilot, co-authored preliminary results. The FY2028 Transformative deadline is forecast for September 3, 2027.

For any mechanism: Find out which institutes and offices co-funded recent cohorts in your area. If your work fits NIEHS, NIDCD, NIMH, NIGMS, or ORIVA priorities, say so plainly in the application. Co-funding decisions are made on scored applications, and a clear mission fit gives an institute a reason to pay for one that falls just short of the Common Fund cutoff.

The 2026 numbers show a program that is getting smaller in award count and larger in dollars per award. The applicants who do best will be the ones whose ideas, and whose written case for them, justify a five-year, multi-million-dollar commitment.